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K103N mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) confers high-level resistance against non-
nucleoside RT inhibitors (NNRTIs) and it easily occurs partly because it arises by a single nucleotide substitution from wild-type K103. There are
polymorphisms at codon 103 of HIV-1 RT. We found K103R polymorphic mutation in 3.3% of treatment-naive HIV-1-infected patients. R103N
does not seem to occur as easily as K103N because R103N requires two nucleotide substitutions. To induce NNRTI resistance-associated
mutations, HIV-1K103R was propagated in the presence of increasing concentrations of efavirez (EFV) or nevirapine (NVP). V179D emerged in all
three EFV cultures and in two of four NVP cultures. R103G emerged by a single nucleotide substitution in one of three EFV cultures. R103N did
not emerge in any of 7 NNRTI cultures. Analysis of recombinant HIV-1s showed that HIV-1K103R/V179D was significantly resistant and HIV-
1K103G was moderately resistant against EFV and NVP.
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IntroductionThe emergence of human immunodeficiency virus type 1
(HIV-1) variants resistant to antiretroviral agents is one of
the most common causes for therapeutic failure in infected
individuals. Fortunately, the availability of drug resistance
testing has substantially improved the ability of clinicians to
deal knowledgeably with drug-resistant HIV-1 strains (Van-
damme et al., 2004). Recent studies, however, have revealed
that certain polymorphic amino acid residues of HIV-1
contribute to drug resistance (Gatanaga et al., 2002; Harrigan
et al., 2005; Tanaka et al., 1997). Even if polymorphic
mutations themselves do not alter drug susceptibility, their
combination with other unreported mutations might confer
significant drug resistance. Such combinations are probably
not included in the current reference tables of drug
resistance-associated mutations and the effect of preexisting0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: higatana@imcj.acc.go.jp (H. Gatanaga).polymorphic mutations on the development of drug resis-
tance is not well taken into consideration (Johnson et al.,
2005).
Non-nucleoside reverse transcriptase inhibitor (NNRTI)-
containing combination of antiretroviral agents are recom-
mended as the first-line regimens for HIV-1-infected
individuals (Yeni et al., 2004). One of the most critical
problems, however, is the easy emergence of NNRTI
resistance-associated mutations, among which the K103N
mutation in reverse transcriptase (RT) is the most common
and important (Bacheler, 1999; De Clercq, 1998; Harrigan et
al., 2005; Nunberg et al., 1991). However, there are
polymorphic mutations at codon 103 of HIV-1 RT (Harrigan
et al., 2005), and their effect on emergence of drug resistance
is not well studied. In this study, we analyzed the polymorphic
frequencies at codon 103 of HIV-1 RT in treatment-naive
patients and determined the effect of such polymorphism on the
development of NNRTI resistance.6) 354 – 362
www.e
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Frequency of K103R in treatment-naı¨ve patients
We analyzed HIV-1 sequences in plasma samples of 211
antiretroviral treatment-naive infected individuals who visited
our clinic from January, 2000 to December, 2003, and found
wild-type K103 in 204 patients (96.7%; nucleotide triplet:
AAA in 202 samples, AAG in 2 samples) and K103R in six
(2.8%; nucleotide triplet: all AGA) and a mixture of these in
one (0.5%; nucleotide triplet: AAA and AGA) (Table 1). Taken
together, K103R was detected in 3.3% of our treatment-naive
patients by direct sequencing.
Induction of EFV-resistant HIV-1 variants
The K103N mutation can arise by a single nucleotide
substitution (AAA to AAC or AAT, AAG to AAC or AAT)
from wild-type K103, while the amino acid substitution from
arginine (R) to asparagine (N) at codon 103, R103N,
necessitates at least two nucleotide substitutions (AGA to
AAC or AAT). Therefore, R103N does not seem to occur as
easily as K103N. In order to find the types of mutations that
can be induced by NNRTI from K103R, the infectious HIV-1
clones harboring wild-type K103 (HIV-1WT) and K103R
(HIV-1K103R) in RT were propagated in MT-2 cells in the
presence of increasing concentrations of EFV, respectively.
The culture supernatant was harvested on day 7 of culture
and used to infect fresh MT-2 cells for the next round of
culture. When the virus began to propagate in the presence
of the drug, the drug concentration was increased. HIV-1WT
harboring nucleotide triplet AAA at codon 103 of RT, was
propagated in two independent cultures (Figs. 1A and B). In
one culture, I178M mutation first emerged at 11 weeks of
passages and K103N was added to it at 22 weeks (Fig. 1A).
In the other culture, Y181C first emerged at 6 weeks, and
K101E and V179D were combined to it at 16 weeks (Fig.
1B). Furthermore, V106I and V108I were added to them at
20 weeks, but V106I could not be detected by direct
sequencing at 25 weeks (Fig. 1B). In order to determine
the effect of synonymous nucleotide substitution on the
development of EFV resistance, HIV-1WT harboring nucleo-
tide triplet AAG at codon 103 of RT, was also propagated in
the same way (Fig. 1C). K103N emerged at 12 weeks, and
L100I was combined to it at 25 weeks. Considered together,Table 1
Frequency of mutations at codon 103 of HIV-1 RT in treatment-naive patients
Amino acid (nucleotides) Number of patients
K (AAA) 202
K (AAG) 2
R (AGA) 6
K (AAA)/R (AGA)a 1
Total 211
Deduced amino acids and nucleotide triplets at codon 103 of HIV-1 RT are
shown.
a Mixture of K (AAA) and R (AGA).these results indicated it was easy for K103N to emerge as it
arose in two of three cultures of HIV-1WT under the selective
pressure of EFV.
HIV-1K103R was propagated in three independent cultures
(Figs. 1D–F). In one culture, G190A emerged at 11 passages,
and V179D was added at 25 weeks (Fig. 1D). In another
culture, R103G, which has not been reported previously, arose
by a single nucleotide mutation (nucleotide triplet: AGA to
GGA) at 8 weeks, and V106I emerged at 11 weeks (Fig. 1E).
At 22 weeks, V106I could not be detected by direct sequencing
and V108I, V179D, and G190A emerged. Finally, R103G and
V108I could not be detected and V106I re-emerged at 25
weeks (Fig. 1E). In the last culture, V179D emerged at 14
weeks and no other mutations were added to it until the EFV
concentration reached 1000 nM at 25 weeks, suggesting that
the combination of K103R and V179D conferred high-level
resistance to EFV (Fig. 1F). In conclusion, R103N mutation
was not detected in any of the three culture of HIV-1K103R,
although it often arose in cultures of HIV-1WT. Instead of
R103N, R103G occurred by a single nucleotide mutation in
one culture. V179D emerged in all of three cultures of HIV-
1K103R and the combination of K103R and V179D seemed to
confer high-level resistance to EFV.
Clonal determination of amino acid mutations in EFV-resistant
HIV-1 variants
In one culture of HIV-1K103R described above (Fig. 1E),
103G mutation, which has not been reported previously, and
V106I mutation, which is polymorphic (Rhee et al., 2003),
were detected at early passages and the mutation pattern was
complicated with the appearance and disappearance of various
mutations at late passages. Therefore, we decided to analyze
the mutations by cloning at several passages (Table 2). At 14
weeks when EFV concentration had not yet increased, R103G
and V106I emerged in independent clones. However, the
V106I clone without any other acquired mutation was not
detected and every analyzed clone had R103G at 18 weeks
when EFV concentration was increased to 30 nM. These
results indicate that V106I itself conferred little resistance to
EFV to HIV-1K103R and that R103G conferred moderate
resistance. At 20 weeks when EFV concentration was further
increased to 100 nM, 19 of 20 clones had R103G, and one
clone had V106I and V179D. The latter clone still existed at
22 weeks (EFV: 500 nM) at a frequency of 2 of 21, which
suggests that the addition of V106I and V179D to HIV-
1K103R conferred high-level resistance to EFV. At 25 weeks
(EFV: 1000 nM), the clone with V106I, V179D, and G190A
predominated other clones. Considered together, the results
indicate that V106I clone without any other acquired mutation
existed only at the initial EFV concentration (3 nM), and once
EFV concentration was increased, every analyzed clone had
R103G or the combination of K103R, V106I, and V179D,
suggesting that V106I itself conferred little EFV resistance
to HIV-1K103R and that R103G and the combination
K103R, V106I, and V179D conferred significant resistance
to EFV.
Fig. 1. Induced amino acid substitutions under the selective pressure of EFV. HIV-1WT harboring nucleotide triplet AAA (panels A and B), and AAG (panel C) at
codon 103 of RT, and HIV-1K103R (panels D–F) were propagated in MT-2 cells in the presence of increasing concentrations of EFV. Induced amino acid
substitutions were analyzed at several passages by sequencing proviral HIV-1 RT in MT-2 cells.
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Under the selective pressure of EFV, R103N did not emerge
but the unreported R103G appeared instead, and V179D
developed in every culture of HIV-1K103R. To obtain furtherTable 2
Clonal sequence analysis of RT gene of HIV-1 passaged in the presence of EFV
(Fig. 1E)
Weeks
(EFV)
Amino acid Clones/
total
103
(R)
106
(V)
108
(V)
135
(I)
179
(V)
190
(G)
14 (3 nM) – – – – – – 7
G – – – – – 7
– I – – – – 3/17
18 (30 nM) G – – – – – 21
G I – – – – 3/24
20 (100 nM) G I – – – – 10
G – – – – – 9
– I – – D – 1/20
22 (500 nM) G – I – – A 14
G – – – D – 2
– I – – D – 2
G – – – – A 1
G – I – D A 1
G – I V D – 1/21
23 (1000 nM) – I – – D A 7
G – – V D – 6
G – I – – A 5
G – I – D A 1
G – – V D A 1/20
25 (1000 nM) – I – – D A 20/20
Data are deduced amino acids at the positions where mutations were detected.
Identity with original amino acids shown at the top is indicated by the dash
sign.insight on the development of NNRTI resistance from HIV-
1K103R, we passaged HIV-1K103R in the presence of increasing
concentrations of NVP. HIV-1K103R was propagated in four
independent cultures (Figs. 2A–D). In one culture, V179D
emerged first at 10 weeks and V106A, which is well known to
confer significant resistance to NVP (Johnson et al., 2005), was
added to it at 19 weeks (Fig. 2A). In the other three cultures
(Figs. 2B–D), V106A emerged first at 8–10 weeks, and
V179D was combined to it at 16 weeks in one culture (Fig. 2C).
In summary, R103N did not emerge in any of the four cultures
of HIV-1K103R as expected, and V106A appeared in every
culture. V179D, which was observed in all three cultures with
EFV, emerged in two of four cultures with NVP, suggesting that
the combination of K103R and V179D conferred significant
resistance not only to EFV but also to NVP and increased the
viral replication cooperated with V106A in the presence of
NVP.
NNRTI resistance conferred by K103R/V179D and K103G
In order to analyze the effect of each mutation and their
combinations on drug resistance, we constructed a panel of
recombinant HIV-1 clones and determined their IC50 for four
NRTIs, including zidovudine (AZT), lamivudine (3TC),
stavudine (d4T), and tenofovir disoproxil fumarate (TDF),
and two NNRTIs, including EFV and NVP. Drug resistance
assay was performed in triplicate using MAGIC-5 cells
(Table 3) (Hachiya et al., 2001, 2003, 2004). As reported
previously, K103R and V106I alone did not confer signif-
icant drug resistance (Harrigan et al., 2005; Rhee et al.,
2003). Furthermore, their combination, K103R/V106I, did
not exhibit significant drug resistance, although it was observed
Fig. 2. Induced amino acid substitutions under the selective pressure of NVP.
HIV-1K103R was propagated in four cultures (panels A–D) of MT-2 cells in the
presence of increasing concentrations of NVP. Induced amino acid substitu-
tions were analyzed at several passages by sequencing proviral HIV-1 RT in
MT-2 cells.
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(Fig. 1E). The previously unreported mutation K103G,
which emerged in one culture of HIV-1K103R under EFV
pressure, conferred 5.60- and 4.71-fold resistance to EFVand
NVP, respectively. The combination of K103R and V179D,
which was observed in all three cultures of HIV-1K103R under
EFV pressure and in two of four cultures under NVP pressure,
conferred 10.4- and 9.41-fold resistance to EFV and NVP,
respectively, though V179D alone had little effect on EFV
resistance (1.60-fold) but moderate resistance only to NVP
(5.10-fold). Therefore, as expected from the data of emergence
patterns of induced mutations under NNRTI selective pressure,
K103G conferred moderate resistance to EFVand NVP, and the
combination of K103R and V179D conferred high-level
resistance to these NNRTIs.Table 3
Drug susceptibilities of recombinant HIV-1s
HIV-1 Mean IC50 (nM) T SD (fold resistance)
AZT 3TC d4T
Wild-type 30.0 T 3.5 775 T 14 1510 T 200
K103R 17.0 T 1.2 (0.567) 340 T 32 (0.439) 1500 T 120 (0
K103N 14.0 T 1.3 (0.467) 380 T 27 (0.490) 1400 T 130 (0
V106I 19.0 T 2.4 (0.633) 860 T 33 (1.11) 1090 T 70 (0.7
K103G 24.0 T 1.0 (0.800) 1160 T 30 (1.50) 660 T 100 (0
K103R/V106I 29.0 T 1.3 (0.967) 1420 T 80 (1.83) 1200 T 330 (0
V179D 16.0 T 1.5 (0.533) 830 T 23 (1.07) 3600 T 230 (2
K103R/V179D 34.0 T 2.0 (1.13) 1980 T 12 (2.55) 1430 T 140 (0
Drug resistance assay was performed in triplicate using MAGIC-5 cells (Hachiya
recombinant HIV-1 by that of wild-type HIV-1.Decreased replication kinetics of HIV-1K103R/V179D
Finally, we analyzed the effect of single mutations and their
combinations on HIV-1 replication kinetics in MT-2 cells in the
absence and presence of NNRTI (Fig. 3 and Table 4). Each
replication assay was performed in triplicate and repeated three
times. In the absence of NNRTI, K103R and V106I did not
significantly alter HIV-1 replication. Their combination
(K103R/V106I), however, significantly reduced viral replica-
tion (p24 at day 8 of K103R/V106I vs. wild-type: P < 0.05, Fig.
3A and Table 4). K103G also resulted in reduced replication
(K103G vs. wild-type: P < 0.05). V179D tended to reduce HIV-
1 replication but the effect was not statistically significant in our
assay. The combination of K103R and V179D severely
compromised HIV-1 replication (K103R/V179D vs. wild-type:
P < 0.01, Fig. 3A and Table 4). As reported previously, K103N
did not significantly decrease HIV-1 replication (Gianotti et al.,
2004; Schmit et al., 1996).
In the presence of 10 nM EFV, HIV-1 clones harboring wild-
type K103 (HIV-1WT), K103R (HIV-1K103R), V106I (HIV-
1V106I), and K103R/V106I (HIV-1K103R/V106I), failed to prop-
agate and HIV-1 harboring V179D (HIV-1V179D) exhibited
reduced replication compared with that in the absence of
NNRTI (P < 0.05, Fig. 3B and Table 4). HIV-1 clones harboring
K103N (HIV-1K103N), K103G (HIV-1K103G), and the combina-
tion of K103R and V179D (HIV-1K103R/V179D) showed efficient
replication though their replication was slightly reduced
compared with those in the absence of NNRTI. In the presence
of 100 nM NVP, HIV-1K103N, HIV-1K103G, HIV-1V179D, and
HIV-1K103R/V179D exhibited efficient replications (Fig. 3C). The
replication of the other HIV-1 clones was severely compro-
mised. These data of the replication kinetics were well
compatible with the IC50 data (Table 3).
Competitive HIV-1 replication assay using H9 cells
In order to confirm some of the results shown above,
competitive HIV-1 replication assay was performed using H9
cells (Hachiya et al., 2004; Kosalaraksa et al., 1999) (Fig. 4).
Two infectious HIV-1 clones to be compared for their fitness
were mixed and used to infect H9 cells, and their population
changes through weekly passages were determined by theTDF EFV NVP
27.0 T 2.8 2.50 T 0.25 25.5 T 3.6
.993) 23.0 T 1.9 (0.852) 2.40 T 0.34 (0.960) 19.0 T 2.2 (0.745)
.927) 29.0 T 2.2 (1.07) 31.0 T 2.3 (12.4) 1100 T 130 (43.1)
22) 31.0 T 2.0 (1.15) 3.00 T 0.33 (1.20) 20.0 T 1.2 (0.784)
.437) 24.0 T 2.0 (0.889) 14.0 T 1.3 (5.60) 120 T 10 (4.71)
.795) 31.0 T 1.3 (1.15) 3.00 T 0.33 (1.20) 30.0 T 11 (1.18)
.38) 36.0 T 3.0 (1.33) 4.00 T 0.17 (1.60) 130 T 20 (5.10)
.947) 29.0 T 2.7 (1.07) 26.0 T 2.0 (10.4) 240 T 12 (9.41)
et al., 2001, 2003, 2004). Fold resistance was calculated by dividing IC50 of
Fig. 3. Replication kinetics of recombinant HIV-1 clones in the absence and presence of NNRTIs. Recombinant HIV-1 clones were propagated in MT-2 cells in the
absence (panel A) and presence of 10 nM EFV (panel B) or 100 nM NVP (panel C). The concentration of p24 in the culture medium was measured every other day.
The assay was performed in triplicate and repeated three times and the data represent the logarithmic mean values of p24 concentrations.
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absence of NNRTI (Fig. 4A), and in the presence of EFV
(3 nM) (Fig. 4B) and NVP (30 nM) (Fig. 4C), HIV-1WT and
HIV-1K103R showed comparable replication efficiency, though
the replication of HIV-1K103R may be a little smaller than
that of HIV-1WT in the absence of NNRTI and in the
presence of NVP. HIV-1K103N was slowly outgrown by HIV-
1WT in the absence of NNRTI and it was still detectable at 3
weeks of competitive culture (wild-type:K103N = 91%:9%)
(Fig. 4D). In the presence of EFV (10 nM) (Fig. 4E) and
NVP (100 nM) (Fig. 4F), however, HIV-1K103N readily
outgrew HIV-1WT. HIV-1K103R/V179D was predominated by
HIV-1WT in the absence of NNRTI (Fig. 4G), though it
readily outgrew HIV-1WT in the presence of EFV (10 nM)Table 4
Replication ability of recombinant HIV-1s
HIV-1 Logarithmic mean T SD of p24 (ng/ml) at day 8
No drug 10 nM EFV 100 nM NVP
Wild-type 2.437 T 0.309 0.021 T 0.134 0.003 T 0.257
K103R 2.289 T 0.343 0.284 T 0.102 0.188 T 0.266
K103N 2.422 T 0.273 1.477 T 0.287 1.759 T 0.257
V106I 2.243 T 0.777 0.128 T 0.137 0.063 T 0.105
K103G 1.579 T 0.285 0.789 T 0.571 0.658 T 0.399
K103R/V106I 1.534 T 0.245 0.064 T 0.096 0.164 T 0.096
V179D 1.764 T 0.450 0.431 T 0.347 0.805 T 0.288
K103R/V179D 1.159 T 0.330 1.339 T 0.208 0.697 T 0.315
Recombinant HIV-1 clones were propagated in MT-2 cells in the absence and
presence of 10 nM EFVor 100 nM NVP (Fig. 3). The assay was performed in
triplicate and repeated three times. The logarithmic mean values and SD of p24
concentrations in the culture media at day 8 were shown.(Fig. 4H) and NVP (100 nM) (Fig. 4I). These data of
competitive replication assay were well compatible with
replication kinetic data (Fig. 3) and confirmed that the
combination of K103R and V179D reduced viral replication
in the absence of NNRTI though K103R alone had little
impact on viral replication ability.
Discussion
K103R mutation in RT was detected in 3.3% of our
treatment-naive patients and was not associated with NNRTI
resistance in our recombinant HIV-1 experiments. It was also
reported that K103R was most often observed in individuals
not receiving NNRTI among patients with known treatment
history (Harrigan et al., 2005). Taken together, K103R can be
considered a naturally occurring polymorphism in HIV-1 RT
and is not associated with NNRTI exposure or resistance.
K103N is the most commonly observed NNRTI resistance-
associated mutation, which is considered to arise by a single
nucleotide mutation from wild-type K103. However, R103N,
the same amino acid substitution from K103R, which
necessitates two nucleotide substitutions, did not occur in our
in vitro induction of NNRTI resistance. Instead, a previously
unreported mutation, R103G, which consisted of a single
nucleotide substitution, was observed and shown to confer
moderate resistance to EFV and NVP. It is worth noting that
103S, a rare mutation, was reported to follow K103R in three
cases in the British Columbia database and was shown to
confer high-level resistance to NNRTIs by analyzing recom-
binant HIV-1s (Harrigan et al., 2005). R103S mutation can also
arise by a single nucleotide substitution from K103R, though
Fig. 4. Competitive HIV-1 replication assay in H9 cells. Two infectious HIV-1 clones to be compared for their fitness (HIV-1WT vs. HIV-1K103R in panels A–C, HIV-
1WT vs. HIV-1K103N in panels D–F, and HIV-1WT vs. HIV-1K103R/V179D in panels G–I) were mixed and used to infect H9 cells in the absence (panels A, D, and G)
and presence of EFV (3 nM in panel B, 10 nM in panels E and H) or NVP (30 nM in panel C, 100 nM in panels F and I). The cell-free supernatant was transferred to
fresh H9 cells every 7 days. High-molecular-weight DNAs extracted from infected cells on day 1 of the culture (0 week) and at the end of each passage (1, 2, and 3
weeks) were subjected to nucleotide sequencing, and proportion of Lys and Arg at position 103 (panels A–C and G–I), those of Lys and Asn at position 103 (panels
D–F), and those of Val and Asp at position 179 (panels G–I) were determined.
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Virological analysis of such polymorphism-specific mutations
seems important, considering that the prevalence of 103S
increased over fourfold in both Virco and British Columbia
databases from 1998 to 2002 (Harrigan et al., 2005).
V179D is not included in the current table of drug resistance
mutations by the International AIDS Society-USA Drug
Resistance Mutations Group (Johnson et al., 2005), though it
was reported to confer a small resistance to NNRTIs (Byrnes et
al., 1993; Kleim et al., 1996; Winslow et al., 1996; Young et al.,
1995). In the present study, V179D was often induced by
NNRTIs in HIV-1 harboringK103R. In StanfordUniversity HIV
Drug Resistance Database (http://hivdb.stanford.edu/index.
html), there are 57 registered clinical isolates harboring
K103R and V179D mutations, and most of them are derived
from the patients with a history of NNRTI treatment, which
indicates that our in vitro observation actually often occurs in the
patients. The combination of K103R andV179D conferred high-
level resistance to EFV and NVP in our assay, suggesting that
certain polymorphic mutation can alter the frequency of
emergence of resistance-associated mutations and that the
combination of a certain polymorphic mutation and a minor
resistance-associated mutation can confer high-level resistance
even if the polymorphism itself is not associated with drug
resistance. The combination of K103R and V179D compli-
cated viral replication though K103R alone did not signifi-
cantly alter replication kinetics (Figs. 3A and 4A, G). Theseresults suggest that HIV-1K103R/V179D might disappear rapidly
and be replaced by HIV-1K103R or HIV-1WT after the
discontinuation of NNRTI treatment, and that routine geno-
typic assay might not detect this combination in patients
during NNRTI-free periods even if V179D emerged in patients
during NNRTI-based therapy. On the other hand, K103N did
not severely impair HIV-1 replication (Figs. 3A and 4D), in
agreement with the recent studies reporting that HIV-1K103N
replicates comparably with HIV-1WT and that K103N mutation
remains stably detectable for a long time after the cessation of
the NNRTI administration (Collins et al., 2004; Gianotti et al.,
2004; Schmit et al., 1996).
Certain polymorphic amino acid residues in HIV-1 strains are
associated with HIV-1 drug resistance (Gatanaga et al., 2002;
Harrigan et al., 2005; Tanaka et al., 1997). It is also known that
certain drug resistance-conferring amino acid substitutions
found in one subtype HIV-1 isolated from patients under therapy
may be detected in HIV-1 of other subtypes from untreated
individuals (Cornelissen et al., 1997; Quinones-Mateu et al.,
1998). Moreover, a recent study revealed that HIV-2 strains
harbor specific patterns of natural polymorphism and resistance
(Colson et al., 2004). More attention should be given to
resistance-associated mutations that are specifically derived
from certain polymorphisms and certain subtypes. In vitro
induction of drug resistance to HIV strains harboring such
polymorphisms and subtypes is a reasonable strategy for
analyzing such mutations.
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HIV-1 sequences in treatment-naive patients
We analyzed HIV-1 sequences in plasma samples of 211
antiretroviral treatment-naive infected individuals who visited
the outpatient clinic of the AIDS Clinical Center, International
Medical Center of Japan from January, 2000 to December,
2003. The Institutional Review Board approved this study
(IMCJ-H13-80) and a written informed consent was obtained
from all the participants. Viral RNA was extracted from
plasma samples with Smi-test nucleic acid extraction kit
(Genome Science, Fukushima, Japan). The HIV-1 RT gene
was amplified by RT-PCR using One Step RNA PCR Kit
(Takara Shuzo, Otsu, Japan). Nested PCR was conducted
subsequently to amplify enough DNA for direct sequencing.
The primer sets were T1 and T4 for the first PCR, and T12
and T15 for the second PCR (Hachiya et al., 2004). Specific
precautions, including physical separation of processing areas,
were taken to avoid template and amplified product carryover.
Stringent quality control to prevent PCR contamination was
employed to protect against cross-contamination of product
DNA. Direct sequencing was performed using dye terminators
(BigDye Terminator Cycle Sequencing Ready Reaction Kit;
Applied Biosystems, Foster, CA) and model 3700 automated
DNA sequencer (Applied Biosystems). Amino acid sequences
were deduced with Genetyx-Win program version 6.1
(Software Development, Tokyo).
Antiviral agents and cells
EFV, NVP, and 3TC were generously provided by Merck
Co. Inc. (Rahway, NJ), Boehringer Ingelheim Pharmaceutics
Inc. (Ridgefield, CT), and Nippon Glaxo-SmithKline (Tokyo,
Japan), respectively. AZT and d4T were purchased from Sigma
Co. (Tokyo, Japan). TDF was purchased from Moravek
Biochemicals (Brea, CA). COS-7 cells and MT-2 cells were
grown in Dulbecco’s modified eagle medium (DMEM) and
RPMI 1640, respectively, supplemented with 10% fetal calf
serum (FCS), penicillin (100 U/ml), and streptomycin (0.1 mg/
ml). MAGIC-5 cells (CCR5 and CD4 expressing HeLa-LTR-h-
gal cells) (Hachiya et al., 2001, 2003, 2004) were grown in
DMEM supplemented with 10% FCS, hygromycin B (0.1 mg/
ml) (Invitrogen Co., San Diego, CA) and blasticidin (1000 ng/
ml) (Funakoshi, Tokyo).
Generation of recombinant HIV-1 clones
The desired mutations were introduced into the XmaI–NheI
region of pTZNX, which encodes Gly-15 to Ala-267 of HIV-1
RT (strain BH 10), by the oligonucleotide-based mutagenesis
method (Hachiya et al., 2004; Kodama et al., 2001). The
XmaI–NheI fragment was inserted into pNLH219Q, which was
modified from pNL101 and encoded the full genome of HIV-1.
pNLH219Q harbors H219Q mutation in HIV-1 Gag region,
which facilitated HIV-1 replication in MT-2 cells (Gatanaga et
al., 2002). Determination of the nucleotide sequences ofplasmids confirmed that each clone had the desired mutations
but no unintended mutations. Each molecular clone was
transfected into COS-7 cells with GenePORTER Transfection
Reagent (Gene Therapy Systems, San Diego, CA), and thus
obtained virions were harvested 48 h after transfection and
stored at 80 -C until use.
Induction of HIV-1 resistant to NNRTIs
The infectious HIV-1 clones harboring wild-type K103
(HIV-1WT) or K103R (HIV-1K103R) in RT were propagated in
MT-2 cells in the presence of increasing concentrations of EFV
and NVP, respectively (Gatanaga et al., 2002; Nunberg et al.,
1991; Tanaka et al., 1997; Yoshimura et al., 1999). Briefly,
MT-2 cells (1  105) were exposed to HIV-1WT or HIV-1K103R
(500 blue cell-forming units [BFU] in MAGIC-5 cells)
(Hachiya et al., 2001, 2003, 2004) and cultured in the presence
of EFV and NVP at the initial concentrations of 3 nM and 30
nM, respectively. Viral replication was monitored by observa-
tion of the cytopathic effect in MT-2 cells. The culture
supernatant was harvested on day 7 of culture and used to
infect fresh MT-2 cells for the next round of culture. When the
virus began to propagate in the presence of the drug, the drug
concentration was increased. This selection was carried out for
a total of 25 and 19 passages for cultures with EFV and NVP,
respectively. Proviral DNAs from lysates of infected MT-2
cells from several passages were sequenced as indicated.
Proviral HIV-1 RT gene was amplified and sequenced by using
the primers T1 and T4. When necessary, molecular cloning was
performed by using pT7 Blue T-Vector (Novagen, CA) and
their sequences were analyzed.
Drug susceptibility assay with MAGIC-5 cells
Recombinant HIV-1 susceptibility to various RT inhibitors
(RTIs) was determined in triplicate by using MAGIC-5 cells as
described previously (Hachiya et al., 2001, 2003, 2004).
Briefly, MAGIC-5 cells were infected with adjusted virus
stock (300 BFU) in various concentrations of RTIs, cultured for
48 h, fixed, and stained with 5-bromo-4-chloro-3-indolyl-h-d-
galacto-pyranoside (Takara Shuzo, Ohtsu, Japan). The blue-
stained cells were counted under a light microscope. Drug
concentrations that inhibited 50% of the stained cells of drug-
free control (IC50) were determined by referring to the dose–
response curve.
Replication kinetic assay
MT-2 cells (105) were exposed to each infectious virus
preparation (500 BFU) for 2 h, washed twice with PBS, and
cultured in 1 ml of complete medium in the presence or
absence of EFV or NVP. The culture supernatants were
harvested every other day, and p24 Gag amounts were
determined by chemiluminescence enzyme immunoassay
(CLEIA) kit (Fuji-Rebio, Tokyo). Replication assays were
performed in triplicate and repeated three times using
independently generated virus preparations.
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Freshly prepared H9 cells (3  105) were exposed to the
mixtures of paired virus preparations (300 BFU each) (HIV-
1WT vs. HIV-1K103R in Figs. 4A–C, HIV-1WT vs. HIV-1K103N
in Figs. 4D–F, and HIV-1WT vs. HIV-1K103R/V179D in Figs.
4G–I) to be examined for their replication ability for 2 h,
washed twice with PBS, and cultured in the absence (Figs. 4A,
D, and G) or presence of EFV (3 nM for Fig. 4B, 10 nM for
Figs. 4E and H) or NVP (30 nM for Fig. 4C, 100 nM for Figs.
4F and I) as describe previously (Hachiya et al., 2004;
Kosalaraksa et al., 1999). On day 1, one-third of infected H9
cells were harvested and washed twice with PBS, and proviral
DNAs were sequenced (0 week). Every 7 days, the supernatant
of the virus culture was transmitted to new uninfected H9 cells,
the cells harvested at the end of each passage (1, 2, and 3
weeks) were subjected to direct DNA sequencing of HIV-1 RT
gene, and the viral population change was determined by the
relative peak height on sequencing electrogram. The persis-
tence of the original amino acid substitution was confirmed for
all infectious clones used in this assay.
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